Douglas Ingram is Chief Executive Officer of Sarepta Therapeutics, Inc. (SRPT). The company reported total compensation of $7,840,666 for fiscal year 2025.
| Salary | $1,171,425 |
|---|---|
| Bonus | $0 |
| Stock awards | $6,000,005 |
| Option awards | $0 |
| Non-equity incentive plan | $649,000 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $20,236 |
| Total | $7,840,666 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Sarepta Therapeutics, Inc. filed April 24, 2026, accession 0001193125-26-177247.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer | $1,171,425 | $0 | $6,000,005 | $0 | $649,000 | $0 | $20,236 | $7,840,666 |
| FY2024 | Chief Executive Officer | $846,902 | $1,111,148 | $0 | $0 | $20,036 | $0 | $0 | $1,978,086 |
| FY2023 | Chief Executive Officer | $799,797 | — | — | — | $842,519 | — | $19,022 | $1,661,338 |
| FY2022 | President and Chief Executive Officer | $740,025 | $0 | $0 | $123,314,818 | $865,829 | $0 | $18,022 | $124,938,694 |
| FY2021 | President and Chief Executive Officer | $729,675 | $0 | $0 | $0 | $799,227 | $0 | $17,422 | $1,546,324 |
Totals as disclosed in each year's own compensation disclosure for Sarepta Therapeutics, Inc..
| Peer-group chief executive median | $16,453,286 |
|---|---|
| Difference from that median | $-8,612,620 |
| Percentile within the disclosed peer group | 6th |
| Peers with a disclosed figure | 16 |
Medians and percentiles are computed across the peer group Sarepta Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Douglas Ingram this page | Chief Executive Officer | $7,840,666 |
| Louise Rodino-Klapac | President, Research and Development and Technical Operations | $4,456,270 |
| Ian Estepan | President, Chief Operating Officer | $4,444,392 |
| Cristin Rothfuss | Executive Vice President, General Counsel | $4,233,623 |
| Ryan Wong | Executive Vice President, Chief Financial Officer | $3,211,867 |
| Dallan Murray | Former Executive Vice President, Chief Customer Officer | $2,742,790 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Sarepta Therapeutics, Inc. compensation brief.
Douglas Ingram's compensation sits inside Sarepta Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.